GO
Loading...

The Race for A Cure

Monday, 2 Jun 2008 | 9:56 AM ET

ImClone's Erbitrux lung cancer drug is grabbing the spotlight, with John Johnson, ImClone Systems CEO and CNBC's Mike Huckman